FDA calendar · June 2022 · built from SEC filings

PDUFA dates June 2022: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in June 2022. The FDA calendar also recorded 19 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in June 2022

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

June 2022: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Jun 2022Month disclosedIMCIVREE® (setmelanotide)RYTMFDA approval—ApprovedSEC 8-K Exhibit 99.1
Jun 2022Month disclosedtebipenemSPROComplete Response Letter—CRL issuedSEC Form 10-K
June 3, 2022Riabni (rituximab-arrx)AMGNLabel expansion—ApprovedopenFDA Drugs@FDA
June 7, 2022Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
June 10, 2022Pemetrexed Ditromethamine (pemetrexed ditromethamine)PFEFDA approval—ApprovedopenFDA Drugs@FDA
June 13, 2022OLUMIANT® (baricitinib)LLYLabel expansion—ApprovedSEC Form 10-Q
June 16, 2022Skyrizi (risankizumab-rzaa)ABBVFDA approval—ApprovedopenFDA Drugs@FDA
June 16, 2022Skyrizi (risankizumab-rzaa)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
June 16, 2022IMCIVREE® (setmelanotide)RYTMLabel expansion—ApprovedopenFDA Drugs@FDA
June 22, 2022Tafinlar (dabrafenib mesylate)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
June 22, 2022Mekinist (trametinib dimethyl sulfoxide)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
June 22, 2022Alimta (pemetrexed)PFEFDA approval—ApprovedopenFDA Drugs@FDA
June 29, 2022—ELTPFDA approval—ApprovedSEC Form 10-K

June 2022: dated readouts

DateDrugCompanyEventIndicationStatusSource
Jun 2022Month disclosed—CANFTopline readoutmoderate to serious psoriasisPositiveSEC Form 10-K
Jun 2022Month disclosedVIASKINDBVTTopline readoutpeanut-allergic toddlers 1 - 3 years of agePositiveSEC Form 10-Q
Jun 2022Month disclosedibudilast (MN-166)MNOVTopline readout—Positivesec_s1
Jun 2022Month disclosedTAVALISSE (fostamatinib)RIGLTopline readout—Missed primary endpointSEC Form 10-Q

June 2022: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
June 30, 2022batoclimab (IMVT-1401)IMVTTrial start—CompletedSEC Form 10-Q
Jun 2022Month disclosedselcodebart (DISC-0974)IRONTrial startanemia of different inflammatory diseasesCompletedSEC Form 10-K

Questions

What PDUFA dates are in June 2022?

0 PDUFA dates fell in June 2022. The FDA calendar also recorded 19 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.